<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.2 20190208//EN" "JATS-archivearticle1-mathml3.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?properties manuscript?><front><journal-meta><journal-id journal-id-type="nlm-journal-id">101758684</journal-id><journal-id journal-id-type="pubmed-jr-id">49062</journal-id><journal-id journal-id-type="nlm-ta">Pancreas (Fairfax)</journal-id><journal-id journal-id-type="iso-abbrev">Pancreas (Fairfax)</journal-id><journal-title-group><journal-title>Pancreas (Fairfax, Va.)</journal-title></journal-title-group><issn pub-type="epub">2471-142X</issn></journal-meta><article-meta><article-id pub-id-type="pmid">31930185</article-id><article-id pub-id-type="pmc">6954104</article-id><article-id pub-id-type="doi">10.17140/POJ-3-110</article-id><article-id pub-id-type="manuscript">NIHMS1061348</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>The Evolving Field of Stereotactic Body Radiation Therapy in Pancreatic Cancer</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Ghaly</surname><given-names>Maged</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A1">1</xref><xref rid="CR1" ref-type="corresp">*</xref></contrib><contrib contrib-type="author"><name><surname>Gogineni</surname><given-names>Emile</given-names></name><degrees>DO</degrees><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Saif</surname><given-names>Muhammad W.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A2">2</xref></contrib></contrib-group><aff id="A1"><label>1</label>Department of Radiation Medicine, Northwell Health Cancer Institute, Lake Success, NY, USA</aff><aff id="A2"><label>2</label>Department of Medical Oncology, Northwell Health Cancer Institute, Lake Success, NY, USA</aff><author-notes><corresp id="CR1"><label>*</label><bold><italic>Corresponding author</italic> Maged Ghaly, MD</bold>, Associate Professor, Department of Radiation Medicine, Northwell Health Cancer Institute, Lake Success, NY, USA; Phone. +1-516-321-3122; Fax. +1-516-470-8445; <email>Mghaly@northwell.edu</email></corresp></author-notes><pub-date pub-type="nihms-submitted"><day>20</day><month>12</month><year>2019</year></pub-date><pub-date pub-type="epub"><day>6</day><month>11</month><year>2019</year></pub-date><pub-date pub-type="ppub"><year>2019</year></pub-date><pub-date pub-type="pmc-release"><day>10</day><month>1</month><year>2020</year></pub-date><volume>3</volume><issue>1</issue><fpage>9</fpage><lpage>14</lpage><!--elocation-id from pubmed: 10.17140/POJ-3-110--><permissions><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This is an open-access article distributed under Creative Commons Attribution 4.0 International License (CC BY 4.0), which allows to copy, redistribute, remix, transform, and reproduce in any medium or format, even commercially, provided the original work is properly cited.</license-p></license></permissions><abstract id="ABS1"><p id="P1">Pancreatic cancer remains a devastating disease with dismal outcomes despite the development of novel chemotherapeutic regimens and radiation techniques. Stereotactic body radiation therapy (SBRT) offers an advantage both in image guidance and radiation dose delivery to direct ablative doses to tumors with acceptable toxicity compared to conventional techniques. Recent literature is clustered with data pertaining to SBRT in patients with resectable, borderline resectable and locally advanced pancreatic tumors. We here present a summary of the current data and highlight the limitations and potential for future growth. Further clinical study in the form of multi-institutional trials is warranted to establish the role of SBRT in combination with new chemo- therapeutic agents as well as a non-invasive alternative to surgery.</p></abstract><kwd-group><kwd>Pancreatic neoplasms</kwd><kwd>Pancreas cancer</kwd><kwd>Radiosurgery</kwd><kwd>Stereotactic</kwd><kwd>Stereotactic body radiation therapy (SBRT)</kwd><kwd>Radiation</kwd><kwd>Radiotherapy</kwd></kwd-group></article-meta></front><body><sec id="S1"><title>INTRODUCTION</title><p id="P2">Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with limited effective therapeutic options and exceedingly high mortality. Currently, a cure may be achieved through resection; recent evidence suggests that neoadjuvant therapy can increase R0 (pathologically negative margin) resection rates with effective local control.<sup><xref rid="R1" ref-type="bibr">1</xref></sup> Stereotactic body radiation therapy (SBRT) has garnered significant interest for pancreatic cancer patients as it is completed quickly over 1&#x02013;5 fractions, requires less time away from full doses of chemotherapy, and is generally much better tolerated than conventional radiographic testing (RT) as a result of more limited target volumes. Favorable results of SBRT for locally advanced pancreatic cancer (LAPC) patients are now leading to the exploration of SBRT for other pancreatic cancer patients.<sup><xref rid="R2" ref-type="bibr">2</xref></sup></p><sec id="S2"><title>SBRT FOR LOCALLY ADVANCED PANCREAS</title><p id="P3">The utility of pancreatic SBRT was established in the locally advanced patient population. With the advent of gemcitabine-based (GEM) chemotherapy, the role of RT for LAPC has become more precarious.<sup><xref rid="R3" ref-type="bibr">3</xref></sup> The European F&#x000e9;d&#x000e9;ration Francophone de Canc&#x000e9;rologie Digestive (FFCD)/The Soci&#x000e9;t&#x000e9; Francophone de Radioth&#x000e9;rapie Oncologique (SFRO) Phase III trial compared GEM alone <italic>versus</italic> induction 5 Fluorouracil (FU) and cisplatin chemoradiation (CRT), followed by maintenance gem.<sup><xref rid="R4" ref-type="bibr">4</xref></sup> Overall survival (OS) was shortened in the CRT arm from 13 to 8.6-months. Higher grade 3 toxicities with CRT were observed during both induction (36% <italic>vs.</italic> 22%) and maintenance (32% <italic>vs.</italic> 18%) phases. Notably, the trial utilized a higher than normal conventionally fractionated 60 Gy dose. The recent success of more aggressive, but increasingly toxic, chemotherapy regimens such as FOLFIRINOX and gem plus nab-paclitaxel have spurred re-examination of local therapy.<sup><xref rid="R5" ref-type="bibr">5</xref>,<xref rid="R6" ref-type="bibr">6</xref></sup> With improved systemic control, local progression may become a more serious issue for survival and quality of life. However, local control rates from standard external beam radiotherapy (EBRT) have been disappointing with 1-year local progression rates of around 50%.<sup><xref rid="R7" ref-type="bibr">7</xref></sup> Furthermore, with two-thirds of patients failing distantly within 1 year, a shorter course approach with minimal interruption to systemic therapy is desirable.<sup><xref rid="R7" ref-type="bibr">7</xref></sup> These factors paved the way for the use of SBRT in pancreatic cancer patients, and initially those with LAPC.</p><p id="P4">The inception of SBRT for pancreatic cancers began at Stanford with a phase I dose escalation study in a LAPC cohort.<sup><xref rid="R8" ref-type="bibr">8</xref></sup> The trial was stopped at a dose of 25 Gy since all patients achieved local control with distant metastasis as the first site of failure. The median survival for all patients was 11-months, with 100% local control. However, despite smaller margins and less acute toxicity, patients treated on the Stanford single-fraction SBRT protocol experienced a high degree of late toxicities (25% grade &#x02265;2).<sup><xref rid="R9" ref-type="bibr">9</xref></sup> Hypofractionated studies showed reduced 1-year grade 2 toxicity to 7.8%. This reduction came without a compromise in disease control. The 1-year local control was 91.5% <italic>vs.</italic> 88.3% (<italic>p</italic>=0.8) for single <italic>vs.</italic> 5-fraction SBRT with median OS of 13.6-months for all patients. More contemporary SBRT series have also largely employed a fractionated approach.<sup><xref rid="R10" ref-type="bibr">10</xref>&#x02013;<xref rid="R14" ref-type="bibr">14</xref></sup> These institutional studies re- veal a median survival of 14&#x02013;15-months, 1-year local control rates of about 80%, and grade 3 toxicities below 10%.<sup><xref rid="R15" ref-type="bibr">15</xref></sup></p><p id="P5">Very recently, a few groups have reported that LAPC patients may have an increased likelihood of undergoing resection after aggressive induction chemotherapy regimens. Recently, the group from Hopkins reported on 88 patients treated from 2010&#x02013;14 with SBRT using gem-based or FOLFIRINOX regimens.<sup><xref rid="R16" ref-type="bibr">16</xref></sup> SBRT doses ranged from 25&#x02013;33 Gy in 5 fractions. The 1-year local control rate was 61%, but with a median OS of 18.4-months for LAPC patients. Notably, 20% of LAPC patients underwent surgery. Resected patients had a median OS of 20.2-months, compared to 12.3-months for unresected cases. Grade 3 toxicity was below 6%. Similar to the study from Hopkins, SBRT data from Moffitt also shows the possibility of downstaging for surgery.<sup><xref rid="R14" ref-type="bibr">14</xref></sup> They reported a 24% surgical conversion rate for LAPC patients receiving FOLFIRINOX chemotherapy. All converted patients achieved an R0 (microscopic negative margin) resection. Any grade 3 or higher toxicity was 7%. Median OS was 34.2-months for patients who underwent resection, and 11.3-months for those who did not. See <xref rid="T1" ref-type="table">Table 1</xref> for a list of SBRT studies for LAPC.</p></sec><sec id="S3"><title>SBRT FOR BORDERLINE RESECTABLE PANCREAS</title><p id="P6">While pancreatic SBRT has been most extensively evaluated in LAPC patients, there is emerging data that SBRT may also benefit patients with borderline resectable pancreas (BRPC) (<xref rid="T2" ref-type="table">Table 2</xref>). The SBRT literature for BRPC largely comes from the Moffitt Cancer Center. Chuong et al reported on a larger series of 73 patients (57 BRPC, 16 LAPC) who received induction gem, docetaxel, and capecitabine (GTX) followed by SBRT.<sup><xref rid="R12" ref-type="bibr">12</xref></sup> SBRT was delivered using 5 consecutive daily fractions targeting the primary tumor with a median dose of 30 Gy (range, 25&#x02013;30 Gy), the region of vasculature involvement was prescribed a median dose of 35 Gy (range, 35&#x02013;50 Gy) using a simultaneous integrated boost (SIB) to further increase the likelihood of tumor regression and R0 resection. After restaging, 56.1% of the BRPC patients underwent surgical resection with all except for one (96.9%) having negative margins. Resected patients had significantly improved median OS (19.3 <italic>vs.</italic> 12.3 months; <italic>p</italic>=0.03) and median progression-free survival (PFS) (12.7 <italic>vs.</italic> 5-months; <italic>p</italic>&#x0003c;0.0001). No acute grade 3 toxicities were reported and the most common acute toxicities were grade 1&#x02013;2 fatigue and nausea. Their subsequent study of 159 patients (110 BRPC, 49 LAPC), surgical resection was performed on 51% of the BRPC patients and R0 resection was achieved in 96%. Portal vein (PV) or superior mesenteric vein (SMV) resection and reconstruction was performed in 34% of BRPC patients. Median OS was significantly higher among patients who had surgery compared to those who did not (34.2 <italic>vs.</italic> 14.0-months; <italic>p</italic>&#x0003c;0.001). Finally, while the prescription doses generally increased compared to the previous publication (primary tumor: median 30 <italic>vs.</italic> 35 Gy; tumor-vessel interface: median 35 <italic>vs.</italic> 40 Gy), the incidence of late grade 3 radiation-related toxicity remained consistently low (~5%).<sup><xref rid="R14" ref-type="bibr">14</xref></sup></p><p id="P7">The feasibility of using SBRT for BRPC is also supported by other studies with more limited numbers of BRPC patients. A study from Johns Hopkins included 88 patients (74 LAPC, 14 BRPC) who received 5-fraction SBRT and reported favorable surgical and SBRT-related toxicity outcomes.<sup><xref rid="R17" ref-type="bibr">17</xref></sup></p><p id="P8">Investigators from the University of Pittsburgh published their experience of 12 patients (7 BRPC, 5 LAPC) who received chemotherapy followed by SBRT prescribed to 36 Gy in 3 fractions (n=7) or 24 Gy in a single fraction (n=5) and then had surgery.<sup><xref rid="R18" ref-type="bibr">18</xref></sup> A high rate of R0 resection was achieved (92%) with minimal toxicity. Pathologic complete response (pCR) was achieved in 25%, which is higher than would be expected with standard EBRT and perhaps signaling that SBRT may have unique histopathologic effects. It is plausible that a higher rate of pCR may be achieved using dose fractionation schedules with a higher biologically effective dose. He et al compared surgical outcomes among BRPC/ LAPC patients who received SBRT (n=29), CRT (n=82), or chemotherapy alone (n=26) and reported R0 resection rates of 90%, 84% and 62%, respectively (<italic>p</italic>=0.02).<sup><xref rid="R19" ref-type="bibr">19</xref></sup> The PCR rate was notably higher among patients who received SBRT (21% <italic>vs.</italic> 4% <italic>vs.</italic> 0%; <italic>p</italic>&#x0003c;0.001).</p><p id="P9">In conclusion, while various neoadjuvant treatment regimens are commonly used for BRPC including standard fractionation CRT, increasing consideration should be given to SBRT based on its clear advantage in increasing R0 resectability with higher PCR rates, and providing improved OS in these patients.</p></sec><sec id="S4"><title>SBRT FOR RESECTABLE PANCREAS</title><p id="P10">The significance of microscopic margin involvement on survival is a controversial topic, with some studies claiming an impact on survival and others finding no such correlation.<sup><xref rid="R20" ref-type="bibr">20</xref></sup> Recent studies based on rigorous pathological examination protocols report R1 rates of well over 70%.<sup><xref rid="R21" ref-type="bibr">21</xref>&#x02013;<xref rid="R25" ref-type="bibr">25</xref></sup> Several studies have shown that residual cancer cells are frequently present in the resection bed even in appropriately staged patients after surgery that is properly performed,<sup><xref rid="R26" ref-type="bibr">26</xref></sup> where even with R0 resections nearly 80% of patients were found to have evidence of microscopic cells left <italic>in situ</italic> at the surgical site.<sup><xref rid="R27" ref-type="bibr">27</xref></sup> In a recent phase III adjuvant chemotherapy trial in patients with resected pancreatic cancer in which many patients had positive margins (0&#x02013;60%) and nodal involvement (63&#x02013;80%), local recurrence rates were 18&#x02013;41%, suggesting the presence of residual disease may benefit from local therapy in addition to systemic therapy.<sup><xref rid="R28" ref-type="bibr">28</xref></sup> Early data from MD Anderson Cancer Center included 86 patients who received gemcitabine-based X-ray telescope (XRT) radiation (30 Gy); 75% of patients were resected, 95% had R0 resections and the median OS for those who completed all therapy was 34-months.<sup><xref rid="R29" ref-type="bibr">29</xref></sup> Their subsequent study of cisplatin and gemcitabine followed by gemcitabine-based chemoradiation in 90 patients with remote procedure call (RPC) revealed an R0 resection rate of 96% and median OS of 31-months.<sup><xref rid="R30" ref-type="bibr">30</xref></sup> Cloyd et al published a unique retrospective study utilizing propensity score weighted methodologies. The authors queried MD Anderson database to identify all patients who received pre-operative chemotherapy or CRT before pancreatectomy for anatomically resectable PDAC between 1999 and 2014. They concluded that the receipt of pre-operative CRT alone was associated with a higher rate of margin-negative resection (91% <italic>vs.</italic> 79%, <italic>p</italic>&#x0003c;0.01), lower rate of positive lymph nodes (53% <italic>vs.</italic> 23%, <italic>p</italic>&#x0003c;0.01), greater treatment effect, reduced incidence of locoregional recurrence (LR) (LR; 16% <italic>vs.</italic> 33%, <italic>p</italic>&#x0003c;0.01) but similar median overall survival (OS; 33.6 <italic>vs.</italic> 26.4-months, <italic>p</italic>=0.09) compared with systemic chemotherapy alone.<sup><xref rid="R31" ref-type="bibr">31</xref></sup> Katz et al, report- ed wider special memorandum account (SMA) margin distance on histological examination on patients who receive pre-operative CRT.<sup><xref rid="R32" ref-type="bibr">32</xref></sup> This suggests that the local effect of CRT may occur primarily through sterilization of the retroperitoneum.</p></sec><sec id="S5"><title>THE IMPACT OF SBRT ON THE TUMOR MICROENVIRONMENT</title><p id="P11">Both SBRT and SRS have been used effectively for the treatment of lung, liver, brain, prostate, and recurrent head and neck cancers, among others.<sup><xref rid="R33" ref-type="bibr">33</xref>&#x02013;<xref rid="R37" ref-type="bibr">37</xref></sup> Damage to tumor cell deoxyribonucleic acid (DNA) is thought to account for only part of the efficacy of hypofractionated regimens.<sup><xref rid="R38" ref-type="bibr">38</xref></sup> Many studies indicate that in addition to the direct impact on DNA, the effects of high-dose radiation on the tumor microenvironment (TME) may play a role in tumor control by SBRT and stereotactic radiosurgery (SRS).<sup><xref rid="R38" ref-type="bibr">38</xref>&#x02013;<xref rid="R41" ref-type="bibr">41</xref></sup> Many studies indicate the effect of a single fraction or hypofractionated radiation therapy in the treatment of pancreatic tumor xenografts.</p><p id="P12">In the stroma of human carcinomas, cancer-associated fibroblasts (CAFs) are the most abundant cell types and play a significant role in tumor cell growth, angiogenesis, and invasiveness (<xref rid="F1" ref-type="fig">Figure 1</xref>).<sup><xref rid="R42" ref-type="bibr">42</xref>&#x02013;<xref rid="R46" ref-type="bibr">46</xref></sup> CAFs are also responsible for the deposition of key extracellular matrix (ECM) proteins (e.g., collagen, fibronectin, and laminin) as well as secreting ECM-degrading enzymes (e.g., matrix metalloproteinases),<sup><xref rid="R42" ref-type="bibr">42</xref>,<xref rid="R43" ref-type="bibr">43</xref></sup> which promotes migration of CAFs and degradation of the ECM, allowing the invasion of tumor cells.<sup><xref rid="R47" ref-type="bibr">47</xref></sup></p><p id="P13"><italic>In vitro</italic> studies have shown that fibroblasts develop an irreversible senescent phenotype when exposed to a dose&#x0003e;10 Gy of radiation, whereas low doses of radiation induce reversible DNA damage without growth arrest. Senescent fibroblasts release proteolytic enzymes, cytokines, growth factors, and reactive oxygen species, creating a protumorigenic environment.<sup><xref rid="R48" ref-type="bibr">48</xref></sup> Radiation doses higher than 10 Gy per fraction are associated with severe vascular damage leading to the deterioration of the TME.<sup><xref rid="R39" ref-type="bibr">39</xref>,<xref rid="R49" ref-type="bibr">49</xref></sup> Although endothelial cell damage has been shown to be a major factor in the biological mechanism of SBRT and SRS, this phenomenon is sometimes transient and may lead to neovasculogenesis <italic>via</italic> hypoxia-inducible factor (HIF)-1 induction.<sup><xref rid="R49" ref-type="bibr">49</xref></sup> Baird et al reported pancreatic tumor regression through activation of type 1 interferon-dependent responses with a single dose of 10 Gy and co-treatment with <italic>cGAMP</italic> or <italic>STING</italic> (simulator of interferon genes) agonists that amplify the radiation-induced antitumor immune response.<sup><xref rid="R50" ref-type="bibr">50</xref>,<xref rid="R51" ref-type="bibr">51</xref></sup> Type 1 interferons (interferon (IFN)-&#x003b1; and IFN-&#x003b2;) are important for activation of both innate and adaptive immune responses and are well-known for their role in viral immunity.<sup><xref rid="R52" ref-type="bibr">52</xref></sup></p><p id="P14">Treatment of pancreatic tumor xenografts with radiation given as 4 Gy in 2 fractions resulted in a switchin tumor-infiltrating macrophages from a protumorigenic M2 phenotype to an antitumorigenic M1 phenotype.<sup><xref rid="R53" ref-type="bibr">53</xref></sup> Likewise, increased infiltration of T-cells into tumors and tumor killing mediated by iNOS+M1 macro- phages through the expression of Type 1 T helper (TH1) cytokines have been reported in murine models of pancreatic cancer and melanoma after low-dose radiation treatment.<sup><xref rid="R53" ref-type="bibr">53</xref>,<xref rid="R54" ref-type="bibr">54</xref></sup> Moreover, many studies have demonstrated M2 polarization after treatment with single high-dose and hypofractionated radiation regimens.<sup><xref rid="R55" ref-type="bibr">55</xref>&#x02013;<xref rid="R57" ref-type="bibr">57</xref></sup> Several clinical trials are underway to determine the effects of combination therapy with radiation and immune checkpoint inhibitors (<xref rid="T3" ref-type="table">Table 3</xref>).<sup><xref rid="R58" ref-type="bibr">58</xref>&#x02013;<xref rid="R60" ref-type="bibr">60</xref></sup></p></sec></sec><sec id="S6"><title>CONCLUSION</title><p id="P15">SBRT has been shown to be safe and effective in pancreatic cancer patients. It offers several advantages over standard EBRT including increased patient convenience, reduced toxicities, and the ability to minimize delays in modern multi-agent chemotherapy. The ability of SBRT to convert patients with borderline and locally advanced tumors to resectable disease with higher percentage of negative resection margins may improve survival. Favorable SBRT outcomes for LAPC patients have paved the way for exploration of SBRT for resectable pancreatic cancer patients, with promising early results. The immunotherapeutic approach has very limited clinical activity to date in pancreatic cancer, it is still unclear how to optimally combine ablative radiation and immunotherapy, including optimal sequencing, radiation dose to effectively overcome the immunosuppressive pancreatic tumor microenvironment.</p></sec></body><back><ref-list><title>REFERENCES</title><ref id="R1"><label>1.</label><mixed-citation publication-type="journal"><name><surname>Heestand</surname><given-names>GM</given-names></name>, <name><surname>Murphy</surname><given-names>JD</given-names></name>, <name><surname>Lowy</surname><given-names>AM</given-names></name>. <article-title>Approach to patients with pancreatic cancer without detectable metastases</article-title>. <source>J Clin Oncol</source>.<year>2015</year>; <volume>33</volume>: <fpage>1770</fpage>&#x02013;<lpage>1778</lpage>. doi: <pub-id pub-id-type="doi">10.1200/JCO.2014.59.7930</pub-id><pub-id pub-id-type="pmid">25918279</pub-id></mixed-citation></ref><ref id="R2"><label>2.</label><mixed-citation publication-type="journal"><name><surname>Pollom</surname><given-names>EL</given-names></name>, <name><surname>Alagappan</surname><given-names>M</given-names></name>, <name><surname>von Eyben</surname><given-names>R</given-names></name>, <etal/>
<article-title>Single-versus multifraction stereotactic body radiation therapy for pancreatic adenocarcinoma: Outcomes and toxicity</article-title>. <source>Int J RadiatOncol Biol Phys</source>. <year>2014</year>; <volume>90</volume>(<issue>4</issue>): <fpage>918</fpage>&#x02013;<lpage>925</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ijrobp.2014.06.066</pub-id></mixed-citation></ref><ref id="R3"><label>3.</label><mixed-citation publication-type="journal"><name><surname>Burris</surname><given-names>HA</given-names></name>, <name><surname>Moore</surname><given-names>MJ</given-names></name>, <name><surname>Andersen</surname><given-names>J</given-names></name>, <etal/>
<article-title>Improvements line therapy for patients with advanced pancreas cancer: A randomized trial</article-title>. <source>J Clin Oncol. 1997</source>; <volume>15</volume>: <fpage>2403</fpage>&#x02013;<lpage>2413</lpage>. doi: <pub-id pub-id-type="doi">10.1200/JCO.1997.15.6.2403</pub-id></mixed-citation></ref><ref id="R4"><label>4.</label><mixed-citation publication-type="journal"><name><surname>Chauffert</surname><given-names>B</given-names></name>, <name><surname>Mornex</surname><given-names>F</given-names></name>, <name><surname>Bonnetain</surname><given-names>F</given-names></name>, <etal/>
<article-title>Phase III trial comparing intensive induction chemoradiotherapy (60 Gy, infusional 5-FU and intermittent cisplatin) followed by maintenance gemcitabine with gemcitabine alone for results of the 2000&#x02013;01 FFCD/SFRO study</article-title>. <source>Ann Oncol. 2008</source>; <volume>19</volume>: <fpage>1592</fpage>&#x02013;<lpage>1599</lpage>. doi: <pub-id pub-id-type="doi">10.1093/annonc/mdn281</pub-id></mixed-citation></ref><ref id="R5"><label>5.</label><mixed-citation publication-type="journal"><name><surname>Von Hoff</surname><given-names>DD</given-names></name>, <name><surname>Ervin</surname><given-names>T</given-names></name>, <name><surname>Arena</surname><given-names>FP</given-names></name>, <etal/>
<article-title>Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine</article-title>. <source>N Engl J Med</source>. <year>2013</year>; <volume>369</volume>: <fpage>1691</fpage>&#x02013;<lpage>1703</lpage>. doi: <pub-id pub-id-type="doi">10.1056/NEJMoa1304369</pub-id><pub-id pub-id-type="pmid">24131140</pub-id></mixed-citation></ref><ref id="R6"><label>6.</label><mixed-citation publication-type="journal"><name><surname>Conroy</surname><given-names>T</given-names></name>, <name><surname>Desseigne</surname><given-names>F</given-names></name>, <name><surname>Ychou</surname><given-names>M</given-names></name>, <etal/>
<article-title>FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer</article-title>. <source>N Engl J Med</source>. <year>2011</year>; <volume>364</volume>: <fpage>1817</fpage>&#x02013;<lpage>1825</lpage>. doi: <pub-id pub-id-type="doi">10.1056/NEJMoa1011923</pub-id><pub-id pub-id-type="pmid">21561347</pub-id></mixed-citation></ref><ref id="R7"><label>7.</label><mixed-citation publication-type="journal"><name><surname>Mukherjee</surname><given-names>S</given-names></name>, <name><surname>Hurt</surname><given-names>CN</given-names></name>, <name><surname>Bridgewater</surname><given-names>J</given-names></name>, <etal/>
<article-title>Gemcitabinebased or capecitabine-based chemoradiotherapy for locally advanced pancreatic cancer (SCALOP): A multicentre, randomised, phase 2 trial</article-title>. <source>Lancet Oncol</source>. <year>2013</year>; <volume>14</volume>: <fpage>317</fpage>&#x02013;<lpage>326</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1470-2045</pub-id>(13)70021&#x02013;4<pub-id pub-id-type="pmid">23474363</pub-id></mixed-citation></ref><ref id="R8"><label>8.</label><mixed-citation publication-type="journal"><name><surname>Koong</surname><given-names>AC</given-names></name>, <name><surname>Le</surname><given-names>QT</given-names></name>, <name><surname>Ho</surname><given-names>A</given-names></name>, <etal/>
<article-title>Phase I study of stereotactic radiosurgery in patients with locally advanced pancreatic cancer</article-title>. <source>Int J Radiat Oncol Biol Phys</source>. <year>2004</year>; <volume>58</volume>: <fpage>1017</fpage>&#x02013;<lpage>1021</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ijrobp.2003.11.004</pub-id><pub-id pub-id-type="pmid">15001240</pub-id></mixed-citation></ref><ref id="R9"><label>9.</label><mixed-citation publication-type="journal"><name><surname>Chang</surname><given-names>DT</given-names></name>, <name><surname>Schellenberg</surname><given-names>D</given-names></name>, <name><surname>Shen</surname><given-names>J</given-names></name>, <etal/>
<article-title>Stereotactic radiotherapy for unresectable adenocarcinoma of the pancreas</article-title>. <source>Cancer</source>. <year>2009</year>; <volume>115</volume>: <fpage>665</fpage>&#x02013;<lpage>672</lpage>. doi: <pub-id pub-id-type="doi">10.1002/cncr.24059</pub-id><pub-id pub-id-type="pmid">19117351</pub-id></mixed-citation></ref><ref id="R10"><label>10.</label><mixed-citation publication-type="journal"><name><surname>Mahadevan</surname><given-names>A</given-names></name>, <name><surname>Jain</surname><given-names>S</given-names></name>, <name><surname>Goldstein</surname><given-names>M</given-names></name>, <etal/>
<article-title>Stereotactic body radiotherapy and gemcitabine for locally advanced pancreatic cancer</article-title>. <source>Int J Radiat Oncol Biol Phys</source>. <year>2010</year>; <volume>78</volume>: <fpage>735</fpage>&#x02013;<lpage>742</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ijrobp.2009.08.046</pub-id><pub-id pub-id-type="pmid">20171803</pub-id></mixed-citation></ref><ref id="R11"><label>11.</label><mixed-citation publication-type="journal"><name><surname>Mahadevan</surname><given-names>A</given-names></name>, <name><surname>Miksad</surname><given-names>R</given-names></name>, <name><surname>Goldstein</surname><given-names>M</given-names></name>, <etal/>
<article-title>Induction gemcitabine and stereotactic body radiotherapy for locally advanced nonmetastatic pancreas cancer</article-title>. <source>Int J Radiat Oncol Biol Phys</source>. <year>2011</year>; <volume>81</volume>: <fpage>e615</fpage>&#x02013;<lpage>622</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ijrobp.2011.04.045</pub-id><pub-id pub-id-type="pmid">21658854</pub-id></mixed-citation></ref><ref id="R12"><label>12.</label><mixed-citation publication-type="journal"><name><surname>Chuong</surname><given-names>MD</given-names></name>, <name><surname>Springett</surname><given-names>GM</given-names></name>, <name><surname>Freilich</surname><given-names>JM</given-names></name>, <etal/>
<article-title>Stereotactic body radiation therapy for locally advanced and borderline resectable pancreatic cancer is effective and well tolerated</article-title>. <source>Int J Radiat Oncol Biol Phys</source>. <year>2013</year>; <volume>86</volume>: <fpage>516</fpage>&#x02013;<lpage>522</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ijrobp.2013.02.022</pub-id><pub-id pub-id-type="pmid">23562768</pub-id></mixed-citation></ref><ref id="R13"><label>13.</label><mixed-citation publication-type="journal"><name><surname>Herman</surname><given-names>JM</given-names></name>, <name><surname>Chang</surname><given-names>DT</given-names></name>, <name><surname>Goodman</surname><given-names>KA</given-names></name>, <etal/>
<article-title>Phase 2 multi-institutional trial evaluating gemcitabine and stereotactic body radiotherapy for patients with locally advanced unresectable pancreatic adenocarcinoma</article-title>. <source>Cancer</source>. <year>2015</year>; <volume>121</volume>: <fpage>1128</fpage>&#x02013;<lpage>1137</lpage>. doi: <pub-id pub-id-type="doi">10.1002/cncr.29161</pub-id><pub-id pub-id-type="pmid">25538019</pub-id></mixed-citation></ref><ref id="R14"><label>14.</label><mixed-citation publication-type="journal"><name><surname>Mellon</surname><given-names>EA</given-names></name>, <name><surname>Hoffe</surname><given-names>SE</given-names></name>, <name><surname>Springett</surname><given-names>GM</given-names></name>, <etal/>
<article-title>Long-term out- comes of induction chemotherapy and neoadjuvant stereotactic body radiotherapy for borderline resectable and locally advanced pancreatic adenocarcinoma</article-title>. <source>Acta Oncol</source>. <year>2015</year>; <volume>54</volume>: <fpage>979</fpage>&#x02013;<lpage>985</lpage>. doi: <pub-id pub-id-type="doi">10.3109/0284186X.2015.1004367</pub-id><pub-id pub-id-type="pmid">25734581</pub-id></mixed-citation></ref><ref id="R15"><label>15.</label><mixed-citation publication-type="journal"><name><surname>Chhabra</surname><given-names>A</given-names></name>, <name><surname>Kaiser</surname><given-names>A</given-names></name>, <name><surname>Regine</surname><given-names>WF</given-names></name>, <name><surname>Chuong</surname><given-names>MD</given-names></name>. <article-title>The expanding role of stereotactic body radiation therapyfor pancreatic cancer: A review of the literature</article-title>. <source>Transl Cancer Res</source>. <year>2015</year>; <volume>4</volume>(<issue>6</issue>): <fpage>659</fpage>&#x02013;<lpage>670</lpage>. doi: <pub-id pub-id-type="doi">10.3978/j.issn.2218-676X.2015.11.01</pub-id></mixed-citation></ref><ref id="R16"><label>16.</label><mixed-citation publication-type="journal"><name><surname>Moningi</surname><given-names>S</given-names></name>, <name><surname>Marciscano</surname><given-names>AE</given-names></name>, <name><surname>Rosati</surname><given-names>LM</given-names></name>, <etal/>
<article-title>Stereotactic body radiation therapy in pancreatic cancer: The new frontier</article-title>. <source>Expert Rev Anticancer Ther</source>. <year>2014</year>; <volume>14</volume>: <fpage>1461</fpage>&#x02013;<lpage>1475</lpage>. doi: <pub-id pub-id-type="doi">10.1586/14737140.2014.952286</pub-id><pub-id pub-id-type="pmid">25183386</pub-id></mixed-citation></ref><ref id="R17"><label>17.</label><mixed-citation publication-type="journal"><name><surname>Moningi</surname><given-names>S</given-names></name>, <name><surname>Dholakia</surname><given-names>AS</given-names></name>, <name><surname>Raman</surname><given-names>SP</given-names></name>, <etal/>
<article-title>The role of stereotactic body radiation therapy for pancreatic cancer: A single-institution experience</article-title>. <source>Ann Surg Oncol</source>. <year>2015</year>; <volume>22</volume>: <fpage>2352</fpage>&#x02013;<lpage>2358</lpage>. doi: <pub-id pub-id-type="doi">10.1245/s10434-014-4274-5</pub-id><pub-id pub-id-type="pmid">25564157</pub-id></mixed-citation></ref><ref id="R18"><label>18.</label><mixed-citation publication-type="journal"><name><surname>Rajagopalan</surname><given-names>MS</given-names></name>, <name><surname>Heron</surname><given-names>DE</given-names></name>, <name><surname>Wegner</surname><given-names>RE</given-names></name>, <etal/>
<article-title>Pathologic response with neoadjuvant chemotherapy and stereotactic body radiotherapy for borderline resectable and locallyadvanced pancreatic cancer</article-title>. <source>Radiat Oncol</source>. <year>2013</year>; <volume>8</volume>: <fpage>254</fpage>. doi: <pub-id pub-id-type="doi">10.1186/1748-717X-8-254</pub-id><pub-id pub-id-type="pmid">24175982</pub-id></mixed-citation></ref><ref id="R19"><label>19.</label><mixed-citation publication-type="journal"><name><surname>He</surname><given-names>J</given-names></name>, <name><surname>Moningi</surname><given-names>S</given-names></name>, <name><surname>Blair</surname><given-names>AB</given-names></name>, <etal/>
<article-title>Surgical outcomes of patients with pancreatic cancer treated with stereotactic body radiation therapy</article-title>. <source>J Clin Oncol</source>. <year>2015</year>; <volume>33</volume>: abstr 341. doi: <pub-id pub-id-type="doi">10.1200/jco.2015.33.3_suppl.341</pub-id></mixed-citation></ref><ref id="R20"><label>20.</label><mixed-citation publication-type="journal"><name><surname>Verbeke</surname><given-names>CS</given-names></name>, <name><surname>Gladhaug</surname><given-names>IP</given-names></name>. <article-title>Resection margin involvement and tumour origin in pancreatic head cancer</article-title>. <source>Br J Surg</source>. <year>2012</year>; <volume>99</volume>(<issue>8</issue>): <fpage>1036</fpage>&#x02013;<lpage>1049</lpage>. doi: <pub-id pub-id-type="doi">10.1002/bjs.8734</pub-id><pub-id pub-id-type="pmid">22517199</pub-id></mixed-citation></ref><ref id="R21"><label>21.</label><mixed-citation publication-type="journal"><name><surname>Verbeke</surname><given-names>CS</given-names></name>, <name><surname>Leitch</surname><given-names>D</given-names></name>, <name><surname>Menon</surname><given-names>KV</given-names></name>, <name><surname>McMahon</surname><given-names>MJ</given-names></name>, <name><surname>Guillou</surname><given-names>PJ</given-names></name>, <name><surname>Anthoney</surname><given-names>A</given-names></name>. <article-title>Redefining the R1 resection inpancreatic cancer</article-title>. <source>Br J Surg</source>. <year>2006</year>; <volume>93</volume>: <fpage>1232</fpage>&#x02013;<lpage>1237</lpage>. doi: <pub-id pub-id-type="doi">10.1002/bjs.5397</pub-id><pub-id pub-id-type="pmid">16804874</pub-id></mixed-citation></ref><ref id="R22"><label>22.</label><mixed-citation publication-type="journal"><name><surname>Menon</surname><given-names>KV</given-names></name>, <name><surname>Gomez</surname><given-names>D</given-names></name>, <name><surname>Smith</surname><given-names>AM</given-names></name>, <name><surname>Anthoney</surname><given-names>A</given-names></name>, <name><surname>Verbeke</surname><given-names>CS</given-names></name>. <article-title>Impact of margin status on survival following pancreatoduodenectomy for cancer: The Leeds Pathology Protocol (LEEPP)</article-title>. <source>HPB (Oxford)</source>. <year>2009</year>; <volume>11</volume>: <fpage>18</fpage>&#x02013;<lpage>24</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1477-2574.2008.00013.x</pub-id><pub-id pub-id-type="pmid">19590619</pub-id></mixed-citation></ref><ref id="R23"><label>23.</label><mixed-citation publication-type="journal"><name><surname>Esposito</surname><given-names>I</given-names></name>, <name><surname>Kleeff</surname><given-names>J</given-names></name>, <name><surname>Bergmann</surname><given-names>F</given-names></name>, <etal/>
<article-title>Most pancreatic cancer resections are R1 resections</article-title>. <source>Ann Surg Oncol</source>. <year>2008</year>; <volume>15</volume>: <fpage>1651</fpage>&#x02013;<lpage>1660</lpage>. doi: <pub-id pub-id-type="doi">10.1245/s10434-008-9839-8</pub-id><pub-id pub-id-type="pmid">18351300</pub-id></mixed-citation></ref><ref id="R24"><label>24.</label><mixed-citation publication-type="journal"><name><surname>Campbell</surname><given-names>F</given-names></name>, <name><surname>Smith</surname><given-names>RA</given-names></name>, <name><surname>Whelan</surname><given-names>P</given-names></name>, <etal/>
<article-title>Classification of R1 resections forpancreatic cancer: The prognostic relevance of tumour involvement within 1 mm of a resection margin</article-title>. <source>Histopathology</source>. <year>2009</year>; <volume>55</volume>: <fpage>277</fpage>&#x02013;<lpage>283</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1365-2559.2009.03376.x</pub-id><pub-id pub-id-type="pmid">19723142</pub-id></mixed-citation></ref><ref id="R25"><label>25.</label><mixed-citation publication-type="journal"><name><surname>Jamieson</surname><given-names>NB</given-names></name>, <name><surname>Foulis</surname><given-names>AK</given-names></name>, <name><surname>Oien</surname><given-names>KA</given-names></name>, <etal/>
<article-title>Positive immobilization margins alone donot influence survival following pancreatico-duodenectomy for pancreatic ductal adenocarcinoma</article-title>. <source>Ann Surg</source>. <year>2010</year>; <volume>251</volume>: <fpage>1003</fpage>&#x02013;<lpage>1010</lpage>. doi: <pub-id pub-id-type="doi">10.1097/SLA.0b013e3181d77369</pub-id><pub-id pub-id-type="pmid">20485150</pub-id></mixed-citation></ref><ref id="R26"><label>26.</label><mixed-citation publication-type="journal"><name><surname>Verbeke</surname><given-names>CS</given-names></name>, <name><surname>Gladhaug</surname><given-names>IP</given-names></name>. <article-title>Resection margin involvement and tumour origin in pancreatic head cancer</article-title>. <source>Br J Surg</source>. <year>2012</year>; <volume>99</volume>: <fpage>1036</fpage>&#x02013;<lpage>1049</lpage>. doi: <pub-id pub-id-type="doi">10.1002/bjs.8734</pub-id><pub-id pub-id-type="pmid">22517199</pub-id></mixed-citation></ref><ref id="R27"><label>27.</label><mixed-citation publication-type="journal"><name><surname>Colbert</surname><given-names>LE</given-names></name>, <name><surname>Hall</surname><given-names>WA</given-names></name>, <name><surname>Nickleach</surname><given-names>D</given-names></name>, <name><surname>Switchenko</surname><given-names>J</given-names></name>, <name><surname>Kooby</surname><given-names>DA</given-names></name>, <name><surname>Landry</surname><given-names>JC</given-names></name>. <article-title>Chemoradiation therapy sequencing for resected pancreatic adenocarcinoma in the National Cancer Data Base</article-title>. <source>Cancer</source>. <year>2014</year>; <volume>120</volume>(<issue>4</issue>): <fpage>499</fpage>&#x02013;<lpage>506</lpage>. doi: <pub-id pub-id-type="doi">10.1002/cncr.28530</pub-id><pub-id pub-id-type="pmid">24390739</pub-id></mixed-citation></ref><ref id="R28"><label>28.</label><mixed-citation publication-type="journal"><name><surname>Neoptolemos</surname><given-names>JP</given-names></name>, <name><surname>Palmer</surname><given-names>DH</given-names></name>, <name><surname>Ghaneh</surname><given-names>P</given-names></name>, <etal/>
<article-title>Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patientswith resected pancreatic cancer (ESPAC-4): A multicentre, open-label, randomised, phase 3 trial</article-title>. <source>Lancet</source>. <year>2017</year>; <volume>389</volume>(10073): <fpage>1011</fpage>&#x02013;<lpage>1024</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S0140-6736(16)32409-6</pub-id><pub-id pub-id-type="pmid">28129987</pub-id></mixed-citation></ref><ref id="R29"><label>29.</label><mixed-citation publication-type="journal"><name><surname>Evans</surname><given-names>DB</given-names></name>, <name><surname>Varadhachary</surname><given-names>GR</given-names></name>, <name><surname>Crane</surname><given-names>CH</given-names></name>, <etal/>
<article-title>Preoperative gemcitabine-based chemoradiation for patients with resectable adenocarcinoma of the pancreatic head</article-title>. <source>J Clin Oncol</source>. <year>2008</year>; <volume>26</volume>: <fpage>3496</fpage>&#x02013;<lpage>3502</lpage>. doi: <pub-id pub-id-type="doi">10.1200/JCO.2007.15.8634</pub-id><pub-id pub-id-type="pmid">18640930</pub-id></mixed-citation></ref><ref id="R30"><label>30.</label><mixed-citation publication-type="journal"><name><surname>Varadhachary</surname><given-names>GR</given-names></name>, <name><surname>Wolff</surname><given-names>RA</given-names></name>, <name><surname>Crane</surname><given-names>CH</given-names></name>, <etal/>
<article-title>Preoperative gemcitabine and cisplatin followed by gemcitabine-based chemoradiation for resectable adenocarcinoma of the pancreatic head.</article-title>
<source>J Clin Oncol</source>. <year>2008</year>; <volume>26</volume>: <fpage>3487</fpage>&#x02013;<lpage>3495</lpage>. doi: <pub-id pub-id-type="doi">10.1200/JCO.2007.15.8642</pub-id><pub-id pub-id-type="pmid">18640929</pub-id></mixed-citation></ref><ref id="R31"><label>31.</label><mixed-citation publication-type="journal"><name><surname>Cloyd</surname><given-names>JM</given-names></name>, <name><surname>Chen</surname><given-names>HC</given-names></name>, <name><surname>Wang</surname><given-names>X</given-names></name>, <etal/>
<article-title>Chemotherapy versus chemoradiation as preoperative therapy for resectable pancreatic ductal adenocarcinoma: A propensity score adjusted analysis</article-title>. <source>Pancreas</source>. <year>2019</year>; <volume>48</volume>(<issue>2</issue>): <fpage>216</fpage>&#x02013;<lpage>222</lpage>. doi: <pub-id pub-id-type="doi">10.1097/MPA.0000000000001231</pub-id><pub-id pub-id-type="pmid">30629022</pub-id></mixed-citation></ref><ref id="R32"><label>32.</label><mixed-citation publication-type="journal"><name><surname>Katz</surname><given-names>MH</given-names></name>, <name><surname>Wang</surname><given-names>H</given-names></name>, <name><surname>Balachandran</surname><given-names>A</given-names></name>, <etal/>
<article-title>Effect of neoadjuvant chemoradiation and surgical technique on recurrence of localizedpancreatic cancer</article-title>. <source>J Gastrointest Surg</source>. <year>2012</year>; <volume>16</volume>: <fpage>68</fpage>&#x02013;<lpage>78</lpage>; discussion 78&#x02013;79. doi: <pub-id pub-id-type="doi">10.1007/s11605-011-1748-7</pub-id><pub-id pub-id-type="pmid">22065318</pub-id></mixed-citation></ref><ref id="R33"><label>33.</label><mixed-citation publication-type="journal"><name><surname>Mahajan</surname><given-names>A</given-names></name>, <name><surname>Ahmed</surname><given-names>S</given-names></name>, <name><surname>McAleer</surname><given-names>MF</given-names></name>, <etal/>
<article-title>Post-operative stereotactic radiosurgery versus observation for completely resected brain metastases: A single-centre, randomised, controlled, phase 3 trial</article-title>. <source>Lancet Oncol</source>. <year>2017</year>; <volume>18</volume>: <fpage>1040</fpage>&#x02013;<lpage>1048</lpage>. doi: <pub-id pub-id-type="doi">10.1016/S1470-2045(17)30414-X</pub-id><pub-id pub-id-type="pmid">28687375</pub-id></mixed-citation></ref><ref id="R34"><label>34.</label><mixed-citation publication-type="journal"><name><surname>Aridgides</surname><given-names>P</given-names></name>, <name><surname>Bogart</surname><given-names>J</given-names></name>. <article-title>Stereotactic body radiation therapy for stage I non-small cell lung cancer</article-title>. <source>Thorac Surg Clin</source>. <year>2016</year>; <volume>26</volume>: <fpage>261</fpage>&#x02013;<lpage>269</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.thorsurg.2016.04.008</pub-id><pub-id pub-id-type="pmid">27427521</pub-id></mixed-citation></ref><ref id="R35"><label>35.</label><mixed-citation publication-type="journal"><name><surname>Qiu</surname><given-names>H</given-names></name>, <name><surname>Moravan</surname><given-names>MJ</given-names></name>, <name><surname>Milano</surname><given-names>MT</given-names></name>, <name><surname>Usuki</surname><given-names>KY</given-names></name>, <name><surname>Katz</surname><given-names>AW</given-names></name>. <article-title>SBRT for hepatocellular carcinoma: 8-year experience from a regional transplant center</article-title>. <source>J Gastrointest Cancer</source>. <year>2018</year>; <volume>49</volume>(<issue>4</issue>): <fpage>463</fpage>&#x02013;<lpage>469</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s12029-017-9990-1</pub-id><pub-id pub-id-type="pmid">28710606</pub-id></mixed-citation></ref><ref id="R36"><label>36.</label><mixed-citation publication-type="journal"><name><surname>Kishan</surname><given-names>AU</given-names></name>, <name><surname>King</surname><given-names>CR</given-names></name>. <article-title>Stereotactic body radiotherapy for low- and intermediate-risk prostate cancer</article-title>. <source>Semin Radiat Oncol</source>. <year>2017</year>; <volume>27</volume>: <fpage>268</fpage>&#x02013;<lpage>278</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.semradonc.2017.02.006</pub-id><pub-id pub-id-type="pmid">28577834</pub-id></mixed-citation></ref><ref id="R37"><label>37.</label><mixed-citation publication-type="journal"><name><surname>Baliga</surname><given-names>S</given-names></name>, <name><surname>Kabarriti</surname><given-names>R</given-names></name>, <name><surname>Ohri</surname><given-names>N</given-names></name>, <etal/>
<article-title>Stereotactic body radiotherapy for recurrent head and neck cancer: A critical review</article-title>. <source>Head Neck</source>. <year>2017</year>; <volume>39</volume>: <fpage>595</fpage>&#x02013;<lpage>601</lpage>. doi: <pub-id pub-id-type="doi">10.1002/hed.24633</pub-id><pub-id pub-id-type="pmid">27997054</pub-id></mixed-citation></ref><ref id="R38"><label>38.</label><mixed-citation publication-type="journal"><name><surname>Kim</surname><given-names>MS</given-names></name>, <name><surname>Kim</surname><given-names>W</given-names></name>, <name><surname>Park</surname><given-names>IH</given-names></name>, <etal/>
<article-title>Radiobiological mechanisms of stereotactic body radiation therapy and stereotactic radiation surgery</article-title>. <source>Radiat Oncol J</source>. <year>2015</year>; <volume>33</volume>: <fpage>265</fpage>&#x02013;<lpage>275</lpage>. doi: <pub-id pub-id-type="doi">10.3857/roj.2015.33.4.265</pub-id><pub-id pub-id-type="pmid">26756026</pub-id></mixed-citation></ref><ref id="R39"><label>39.</label><mixed-citation publication-type="journal"><name><surname>Song</surname><given-names>CW</given-names></name>, <name><surname>Lee</surname><given-names>YJ</given-names></name>, <name><surname>Griffin</surname><given-names>RJ</given-names></name>, <etal/>
<article-title>Indirect tumor cell death after high-dose hypofractionated irradiation: Implications for stereotactic body radiation therapy and stereotactic radiation surgery</article-title>. <source>Int J Radiat Oncol Biol Phys</source>. <year>2015</year>; <volume>93</volume>: <fpage>166</fpage>&#x02013;<lpage>172</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ijrobp.2015.05.016</pub-id><pub-id pub-id-type="pmid">26279032</pub-id></mixed-citation></ref><ref id="R40"><label>40.</label><mixed-citation publication-type="journal"><name><surname>Park</surname><given-names>HJ</given-names></name>, <name><surname>Griffin</surname><given-names>RJ</given-names></name>, <name><surname>Hui</surname><given-names>S</given-names></name>, <name><surname>Levitt</surname><given-names>SH</given-names></name>, <name><surname>Song</surname><given-names>CW</given-names></name>. <article-title>Radiation-induced vascular damage in tumors: implications of vascular damage in ablative hypofractionated radiotherapy (SBRT and SRS)</article-title>. <source>Radiat Res</source>. <year>2012</year>; <volume>177</volume>: <fpage>311</fpage>&#x02013;<lpage>327</lpage>. doi: <pub-id pub-id-type="doi">10.1667/rr2773.1</pub-id><pub-id pub-id-type="pmid">22229487</pub-id></mixed-citation></ref><ref id="R41"><label>41.</label><mixed-citation publication-type="journal"><name><surname>Brown</surname><given-names>JM</given-names></name>, <name><surname>Carlson</surname><given-names>DJ</given-names></name>, <name><surname>Brenner</surname><given-names>DJ</given-names></name>. <article-title>The tumor radiobiology of SRS and SBRT: Are more than the 5 R&#x02019;s involved?</article-title>
<source>Int J Radiat Oncol Biol Phys</source>. <year>2014</year>; <volume>88</volume>: <fpage>254</fpage>&#x02013;<lpage>262</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ijrobp.2013.07.022</pub-id><pub-id pub-id-type="pmid">24411596</pub-id></mixed-citation></ref><ref id="R42"><label>42.</label><mixed-citation publication-type="journal"><name><surname>Bhowmick</surname><given-names>NA</given-names></name>, <name><surname>Neilson</surname><given-names>EG</given-names></name>, <name><surname>Moses</surname><given-names>HL</given-names></name>. <article-title>Stromal fibroblasts in cancer initiation and progression</article-title>. <source>Nature</source>. <year>2004</year>; <volume>432</volume>: <fpage>332</fpage>&#x02013;<lpage>337</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nature03096</pub-id><pub-id pub-id-type="pmid">15549095</pub-id></mixed-citation></ref><ref id="R43"><label>43.</label><mixed-citation publication-type="journal"><name><surname>Kalluri</surname><given-names>R</given-names></name>, <name><surname>Zeisberg</surname><given-names>M</given-names></name>. <article-title>Fibroblasts in cancer</article-title>. <source>Nat Rev Cancer</source>. <year>2006</year>; <volume>6</volume>: <fpage>392</fpage>&#x02013;<lpage>401</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nrc1877</pub-id><pub-id pub-id-type="pmid">16572188</pub-id></mixed-citation></ref><ref id="R44"><label>44.</label><mixed-citation publication-type="journal"><name><surname>Orimo</surname><given-names>A</given-names></name>, <name><surname>Weinberg</surname><given-names>RA</given-names></name>. <article-title>Stromal fibroblasts in cancer: a novel tumor-promoting cell type</article-title>. <source>Cell Cycle</source>. <year>2006</year>; <volume>5</volume>: <fpage>1597</fpage>&#x02013;<lpage>1601</lpage>. doi: <pub-id pub-id-type="doi">10.4161/cc.5.15.3112</pub-id><pub-id pub-id-type="pmid">16880743</pub-id></mixed-citation></ref><ref id="R45"><label>45.</label><mixed-citation publication-type="journal"><name><surname>Shimoda</surname><given-names>M</given-names></name>, <name><surname>Mellody</surname><given-names>KT</given-names></name>, <name><surname>Orimo</surname><given-names>A</given-names></name>. <article-title>Carcinoma-associated fibroblasts are a rate-limiting determinant for tumour progression</article-title>. <source>Semin Cell Dev Biol</source>. <year>2010</year>; <volume>21</volume>: <fpage>19</fpage>&#x02013;<lpage>25</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.semc-db.2009.10.002</pub-id><pub-id pub-id-type="pmid">19857592</pub-id></mixed-citation></ref><ref id="R46"><label>46.</label><mixed-citation publication-type="journal"><name><surname>Mishra</surname><given-names>P</given-names></name>, <name><surname>Banerjee</surname><given-names>D</given-names></name>, <name><surname>Ben-Baruch</surname><given-names>A</given-names></name>. <article-title>Chemokines at the crossroads of tumor-fibroblast interactions that promote malignancy</article-title>. <source>J Leukoc Biol</source>. <year>2011</year>; <volume>89</volume>: <fpage>31</fpage>&#x02013;<lpage>39</lpage>. doi: <pub-id pub-id-type="doi">10.1189/jlb.0310182</pub-id><pub-id pub-id-type="pmid">20628066</pub-id></mixed-citation></ref><ref id="R47"><label>47.</label><mixed-citation publication-type="journal"><name><surname>Gaggioli</surname><given-names>C</given-names></name>, <name><surname>Hooper</surname><given-names>S</given-names></name>, <name><surname>Hidalgo-Carcedo</surname><given-names>C</given-names></name>, <etal/>
<article-title>Fibroblast- led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells</article-title>. <source>Nat Cell Biol</source>. <year>2007</year>; <volume>9</volume>: <fpage>1392</fpage>&#x02013;<lpage>1400</lpage>. doi: <pub-id pub-id-type="doi">10.1038/ncb1658</pub-id><pub-id pub-id-type="pmid">18037882</pub-id></mixed-citation></ref><ref id="R48"><label>48.</label><mixed-citation publication-type="journal"><name><surname>Arnold</surname><given-names>KM</given-names></name>, <name><surname>Flynn</surname><given-names>NJ</given-names></name>, <name><surname>Raben</surname><given-names>A</given-names></name>, <etal/>
<article-title>The impact of radiation on the tumor microenvironment: Effect of dose and fractionation schedules</article-title>. <source>Cancer Growth Metastasis</source>. <year>2018</year>; <volume>11</volume>: 1179064418761639. doi: <pub-id pub-id-type="doi">10.1177/1179064418761639</pub-id></mixed-citation></ref><ref id="R49"><label>49.</label><mixed-citation publication-type="journal"><name><surname>Maeda</surname><given-names>A</given-names></name>, <name><surname>Chen</surname><given-names>Y</given-names></name>, <name><surname>Bu</surname><given-names>J</given-names></name>, <name><surname>Mujcic</surname><given-names>H</given-names></name>, <name><surname>Wouters</surname><given-names>BG</given-names></name>, <name><surname>DaCosta</surname><given-names>RS</given-names></name>. <article-title>In vivo imaging reveals significant tumor vascular dysfunction and increased tumor hypoxia-inducible factor-1&#x003b1; expression induced by high single-dose irradiation in a pancreatic tumor model</article-title>. <source>Int J Radiat Oncol Biol Phys</source>. <year>2017</year>; <volume>97</volume>: <fpage>184</fpage>&#x02013;<lpage>194</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ijrobp.2016.09.005</pub-id><pub-id pub-id-type="pmid">27816364</pub-id></mixed-citation></ref><ref id="R50"><label>50.</label><mixed-citation publication-type="journal"><name><surname>Deng</surname><given-names>L</given-names></name>, <name><surname>Liang</surname><given-names>H</given-names></name>, <name><surname>Xu</surname><given-names>M</given-names></name>, <etal/>
<article-title>STING-dependent cytosolic DNA sensing promotes radiation-induced type I interferon-dependent antitumor immunity in immunogenic tumors</article-title>. <source>Immunity</source>. <year>2014</year>; <volume>41</volume>: <fpage>843</fpage>&#x02013;<lpage>852</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.immuni.2014.10.019</pub-id><pub-id pub-id-type="pmid">25517616</pub-id></mixed-citation></ref><ref id="R51"><label>51.</label><mixed-citation publication-type="journal"><name><surname>Baird</surname><given-names>JR</given-names></name>, <name><surname>Friedman</surname><given-names>D</given-names></name>, <name><surname>Cottam</surname><given-names>B</given-names></name>, <etal/>
<article-title>Radiotherapy combined with novel STING-targeting oligonucleotides results in regression of established tumors</article-title>. <source>Cancer Res</source>. <year>2016</year>; <volume>76</volume>: <fpage>50</fpage>&#x02013;<lpage>61</lpage>. doi: <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-14-3619</pub-id><pub-id pub-id-type="pmid">26567136</pub-id></mixed-citation></ref><ref id="R52"><label>52.</label><mixed-citation publication-type="journal"><name><surname>Perry</surname><given-names>AK</given-names></name>, <name><surname>Chen</surname><given-names>G</given-names></name>, <name><surname>Zheng</surname><given-names>D</given-names></name>, <name><surname>Tang</surname><given-names>H</given-names></name>, <name><surname>Cheng</surname><given-names>G</given-names></name>. <article-title>The host type I interferon response to viral and bacterial infections</article-title>. <source>Cell Res</source>. <year>2005</year>; <volume>15</volume>: <fpage>407</fpage>&#x02013;<lpage>422</lpage>. doi: <pub-id pub-id-type="doi">10.1038/sj.cr.7290309</pub-id><pub-id pub-id-type="pmid">15987599</pub-id></mixed-citation></ref><ref id="R53"><label>53.</label><mixed-citation publication-type="journal"><name><surname>Prakash</surname><given-names>H</given-names></name>, <name><surname>Klug</surname><given-names>F</given-names></name>, <name><surname>Nadella</surname><given-names>V</given-names></name>, <name><surname>Mazumdar</surname><given-names>V</given-names></name>, <name><surname>Schmitz-Winnen-thal</surname><given-names>H</given-names></name>, <name><surname>Umansky</surname><given-names>L</given-names></name>. <article-title>Low doses of gamma irradiation potentially modifies immunosuppressive tumor microenvironment by retuning tumor-associated macrophages: Lesson from insulinoma</article-title>. <source>Carcinogenesis</source>. <year>2016</year>; <volume>37</volume>: <fpage>301</fpage>&#x02013;<lpage>313</lpage>. doi: <pub-id pub-id-type="doi">10.1093/carcin/bgw007</pub-id><pub-id pub-id-type="pmid">26785731</pub-id></mixed-citation></ref><ref id="R54"><label>54.</label><mixed-citation publication-type="journal"><name><surname>Klug</surname><given-names>F</given-names></name>, <name><surname>Prakash</surname><given-names>H</given-names></name>, <name><surname>Huber</surname><given-names>PE</given-names></name>, <etal/>
<article-title>Low-dose irradiation pro- grams macrophage differentiation to an INOS(+)/M1 phenotype that orchestrates effective T cell immunotherapy</article-title>. <source>Cancer Cell</source>. <year>2013</year>; <volume>24</volume>: <fpage>589</fpage>&#x02013;<lpage>602</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ccr.2013.09.014</pub-id><pub-id pub-id-type="pmid">24209604</pub-id></mixed-citation></ref><ref id="R55"><label>55.</label><mixed-citation publication-type="journal"><name><surname>Chiang</surname><given-names>CS</given-names></name>, <name><surname>Fu</surname><given-names>SY</given-names></name>, <name><surname>Wang</surname><given-names>SC</given-names></name>, <etal/>
<article-title>Irradiation promotes an m2 macrophage phenotype in tumor hypoxia</article-title>. <source>Front Oncol</source>. <year>2012</year>; <volume>2</volume>: <fpage>89</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fonc.2012.00089</pub-id><pub-id pub-id-type="pmid">22888475</pub-id></mixed-citation></ref><ref id="R56"><label>56.</label><mixed-citation publication-type="journal"><name><surname>Okubo</surname><given-names>M</given-names></name>, <name><surname>Kioi</surname><given-names>M</given-names></name>, <name><surname>Nakashima</surname><given-names>H</given-names></name>, <etal/>
<article-title>M2-polarized macrophages contribute to neovasculogenesis, leading to relapse of oral cancer following radiation</article-title>. <source>Sci Rep</source>. <year>2016</year>; <volume>6</volume>: 27548. doi: <pub-id pub-id-type="doi">10.1038/srep27548</pub-id></mixed-citation></ref><ref id="R57"><label>57.</label><mixed-citation publication-type="journal"><name><surname>Seifert</surname><given-names>L</given-names></name>, <name><surname>Werba</surname><given-names>G</given-names></name>, <name><surname>Tiwari</surname><given-names>S</given-names></name>, <etal/>
<article-title>Radiation therapy induces macrophages to suppress T-cell responses against pancreatic tumors in mice</article-title>. <source>Gastroenterology</source>. <year>2016</year>; <volume>150</volume>: 1659.e5&#x02013;1672.e5. doi: <pub-id pub-id-type="doi">10.1053/j.gastro.2016.02.070</pub-id></mixed-citation></ref><ref id="R58"><label>58.</label><mixed-citation publication-type="journal"><name><surname>Kang</surname><given-names>J</given-names></name>, <name><surname>Demaria</surname><given-names>S</given-names></name>, <name><surname>Formenti</surname><given-names>S</given-names></name>. <article-title>Current clinical trials testing the combination of immunotherapy with radiotherapy</article-title>. <source>J Immunother Cancer</source>. <year>2016</year>; <volume>4</volume>: <fpage>51</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s40425-016-0156-7</pub-id><pub-id pub-id-type="pmid">27660705</pub-id></mixed-citation></ref><ref id="R59"><label>59.</label><mixed-citation publication-type="journal"><name><surname>Berberat</surname><given-names>PO</given-names></name>, <name><surname>Kunzli</surname><given-names>BM</given-names></name>, <name><surname>Gulbinas</surname><given-names>A</given-names></name>, <etal/>
<article-title>An audit of outcomes of a series of periampullary carcinomas</article-title>. <source>Eur J SurgOncol</source>. <year>2009</year>; <volume>35</volume>: <fpage>187</fpage>&#x02013;<lpage>191</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ejso.2008.01.030</pub-id></mixed-citation></ref><ref id="R60"><label>60.</label><mixed-citation publication-type="journal"><name><surname>Lafaro</surname><given-names>KJ</given-names></name>, <name><surname>Melstrom</surname><given-names>LG</given-names></name>. <article-title>The paradoxical web of pancreatic cancer tumor microenvironment</article-title>. <source>Am J Pathol</source>. <year>2019</year>; <volume>189</volume>(<issue>1</issue>): <fpage>44</fpage>&#x02013;<lpage>57</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ajpath.2018.09.009</pub-id><pub-id pub-id-type="pmid">30558722</pub-id></mixed-citation></ref></ref-list></back><floats-group><fig id="F1" orientation="portrait" position="float"><label>Figure 1.</label><caption><title>The Paradoxical Web of Pancreatic Cancer Tumor Microenvironment</title><p id="P16">Hematoxylin and eosin (H&#x00026;E) and trichrome staining of pancreatic tumors arising in two KPC mice recapitulating the dense collagen-rich stroma seen in human pancreatic adenocarcinoma tumors. Scale bars Z 100 mm.</p></caption><graphic xlink:href="nihms-1061348-f0001"/></fig><table-wrap id="T1" position="float" orientation="landscape"><label>Table 1.</label><caption><p id="P17">SBRT for Locally Advanced Pancreatic Cancer</p></caption><table frame="box" rules="rows"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" valign="middle" rowspan="1" colspan="1">Study</th><th align="center" valign="middle" rowspan="1" colspan="1">n</th><th align="center" valign="middle" rowspan="1" colspan="1">Dose Fractionation</th><th align="center" valign="middle" rowspan="1" colspan="1">Chemo</th><th align="center" valign="top" rowspan="1" colspan="1">Local control</th><th align="center" valign="middle" rowspan="1" colspan="1">Survival</th><th align="center" valign="middle" rowspan="1" colspan="1">Toxicity</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Koong et al<sup><xref rid="R8" ref-type="bibr">8</xref></sup></td><td align="center" valign="middle" rowspan="1" colspan="1">6</td><td align="center" valign="middle" rowspan="1" colspan="1">25Gy in 1fx (73 Gy2)</td><td align="center" valign="middle" rowspan="1" colspan="1">None</td><td align="center" valign="top" rowspan="1" colspan="1">100% @ 1 year</td><td align="left" valign="middle" rowspan="1" colspan="1">Median 8 mo</td><td align="left" valign="middle" rowspan="1" colspan="1">33% acute G3+</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Chang et al<sup><xref rid="R9" ref-type="bibr">9</xref></sup></td><td align="center" valign="middle" rowspan="1" colspan="1">77</td><td align="center" valign="middle" rowspan="1" colspan="1">25Gy in 1fx (73 Gy2)</td><td align="center" valign="middle" rowspan="1" colspan="1">Gemcitabine</td><td align="center" valign="top" rowspan="1" colspan="1">84% @ 1 year</td><td align="left" valign="middle" rowspan="1" colspan="1">Median 12 mo</td><td align="left" valign="middle" rowspan="1" colspan="1">25% G2+ @ 1yr</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Mahadevan et al<sup><xref rid="R11" ref-type="bibr">11</xref></sup></td><td align="center" valign="middle" rowspan="1" colspan="1">39</td><td align="center" valign="middle" rowspan="1" colspan="1">24&#x02013;36Gy in 5fx (30&#x02013;50 Gy2)</td><td align="center" valign="middle" rowspan="1" colspan="1">Gemcitabine</td><td align="center" valign="top" rowspan="1" colspan="1">85% crude</td><td align="left" valign="middle" rowspan="1" colspan="1">Median 20 mo</td><td align="left" valign="middle" rowspan="1" colspan="1">9% late G3+</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Herman et al<sup><xref rid="R13" ref-type="bibr">13</xref></sup></td><td align="center" valign="middle" rowspan="1" colspan="1">49</td><td align="center" valign="middle" rowspan="1" colspan="1">33Gy in 5fx (46 Gy2)</td><td align="center" valign="middle" rowspan="1" colspan="1">Gemcitabine</td><td align="center" valign="top" rowspan="1" colspan="1">78% @ 1 year</td><td align="left" valign="middle" rowspan="1" colspan="1">Median 13.9 mo</td><td align="left" valign="middle" rowspan="1" colspan="1">12% acute G3+ 11% late G2+</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Moningi et al<sup><xref rid="R17" ref-type="bibr">17</xref></sup></td><td align="center" valign="middle" rowspan="1" colspan="1">88</td><td align="center" valign="middle" rowspan="1" colspan="1">25&#x02013;33Gy in 5fx (31&#x02013;46 Gy2)</td><td align="center" valign="middle" rowspan="1" colspan="1">Gemcitabine or FOLFIRINOX</td><td align="center" valign="top" rowspan="1" colspan="1">61% @ 1 year</td><td align="left" valign="middle" rowspan="1" colspan="1">Median 18.4 mo</td><td align="left" valign="middle" rowspan="1" colspan="1">3% acute G3+ 6% late G2+</td></tr></tbody></table></table-wrap><table-wrap id="T2" position="float" orientation="landscape"><label>Table 2.</label><caption><p id="P18">SBRT for Borderline Resectable Pancreatic Cancer</p></caption><table frame="box" rules="rows"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><thead><tr><th align="center" valign="middle" rowspan="1" colspan="1">Study</th><th align="center" valign="middle" rowspan="1" colspan="1">n</th><th align="center" valign="middle" rowspan="1" colspan="1">Dose Fractionation</th><th align="center" valign="middle" rowspan="1" colspan="1">Chemo</th><th align="center" valign="middle" rowspan="1" colspan="1">Survival</th><th align="center" valign="middle" rowspan="1" colspan="1">Conversion<break/>rate</th><th align="center" valign="middle" rowspan="1" colspan="1">R0</th><th align="center" valign="middle" rowspan="1" colspan="1">pCR</th><th align="center" valign="middle" rowspan="1" colspan="1">Toxicity</th></tr></thead><tbody><tr><td align="left" valign="middle" rowspan="1" colspan="1">Chuong et al<sup><xref rid="R12" ref-type="bibr">12</xref></sup></td><td align="center" valign="middle" rowspan="1" colspan="1">73 (78% BRPC)</td><td align="center" valign="middle" rowspan="1" colspan="1">25&#x02013;50Gy in 5fx (31&#x02013;83 Gy2)</td><td align="center" valign="middle" rowspan="1" colspan="1">GTX</td><td align="center" valign="middle" rowspan="1" colspan="1">Median 16.4m 72% @ 1 year</td><td align="center" valign="middle" rowspan="1" colspan="1">56%</td><td align="center" valign="middle" rowspan="1" colspan="1">97%</td><td align="left" valign="middle" rowspan="1" colspan="1">Not reported</td><td align="left" valign="middle" rowspan="1" colspan="1">0% acute G3+ 5% late G3+</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Mellon et al<sup><xref rid="R14" ref-type="bibr">14</xref></sup></td><td align="center" valign="middle" rowspan="1" colspan="1">159 (69% BRPC)</td><td align="center" valign="middle" rowspan="1" colspan="1">30&#x02013;40 Gy in 5fx (40&#x02013;60 Gy2</td><td align="center" valign="middle" rowspan="1" colspan="1">GTX</td><td align="center" valign="middle" rowspan="1" colspan="1">Median 19.2 m</td><td align="center" valign="middle" rowspan="1" colspan="1">51%</td><td align="center" valign="middle" rowspan="1" colspan="1">96%</td><td align="center" valign="middle" rowspan="1" colspan="1">7%</td><td align="left" valign="middle" rowspan="1" colspan="1">7% acute &#x00026; late G3+</td></tr><tr><td align="left" valign="middle" rowspan="1" colspan="1">Rajagopalan et al <sup><xref rid="R18" ref-type="bibr">18</xref></sup></td><td align="center" valign="middle" rowspan="1" colspan="1">12 (58% BRPC)</td><td align="center" valign="middle" rowspan="1" colspan="1">36 Gy in 3fx (66 Gy2) 24 Gy in 1fx (68 Gy2)</td><td align="center" valign="middle" rowspan="1" colspan="1">Gemcitabine-Capecitabine</td><td align="center" valign="middle" rowspan="1" colspan="1">Median 47.2 m 92% @ 1 year</td><td align="center" valign="middle" rowspan="1" colspan="1">100%</td><td align="center" valign="middle" rowspan="1" colspan="1">92%</td><td align="center" valign="middle" rowspan="1" colspan="1">25%</td><td align="left" valign="middle" rowspan="1" colspan="1">0% acute G3+</td></tr></tbody></table></table-wrap><table-wrap id="T3" position="float" orientation="portrait"><label>Table 3.</label><caption><p id="P19">Ongoing Pancreatic Trials</p></caption><table frame="box" rules="rows"><colgroup span="1"><col align="left" valign="middle" span="1"/><col align="left" valign="middle" span="1"/></colgroup><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">Unresectable pancreatic cancer</td><td align="center" valign="top" rowspan="1" colspan="1"><ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT01926197">NCT01926197</ext-link></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Borderline resectable pancreatic cancer</td><td align="center" valign="top" rowspan="1" colspan="1"><ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT01992705">NCT01992705</ext-link>, <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT02308722">NCT02308722</ext-link>, <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT01446458">NCT01446458</ext-link></td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">Resectable pancreatic cancer</td><td align="center" valign="top" rowspan="1" colspan="1"><ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT03704662">NCT03704662</ext-link>, <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT023476I8">NCT02347618</ext-link>, <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT02318095">NCT02318095</ext-link>, <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT02208024">NCT02208024</ext-link>, <ext-link ext-link-type="ClinicalTrials.gov" xlink:href="NCT01446458">NCT01446458</ext-link></td></tr></tbody></table></table-wrap></floats-group></article>